Evan Lippman sold $680K of TEVA stock

Evan Lippman, EVP, Business Development of Teva Pharmaceutical Industries Ltd (TEVA), sold 18,600 shares of TEVA stock worth $680K, per an SEC Form 4 filed Aug 19, 2026.

The sale was pre-arranged (a 10b5-1 plan or an option exercise), not a fresh decision.

The trade happened on Aug 17, 2026, 2 days before it was made public.

TEVA has moved +16.9% since the trade date, from $36.46 to $42.61 (Nov 6, 2026 close).